April 27, 2018 7:41am

I welcomed Thursday’s upside in more ways than just having been oversold and unrecognized

However, recently timing shows that much of any positive swings are harvested quickly

 

There will be a tug-of-war to retain the pricing

 

Pre-open indications: 1 BUY

Where the understanding of the indications sheds light on share pricing!


Lower to mixed open expected

Dow futures are DOWN -0.40% (-97 points) and NASDAQ futures UP +0.20% (+14 points)

 

U.S. stock index futures fluctuated ahead of Friday's open,

European markets were slightly higher

Asia markets higher as investors eye the inter-Korean Summit;

 

Data docket: advance estimates of the gross domestic product (GDP) figures will be released for the first quarter at 8:30 a.m. ET, along with the employment cost index. Consumer sentiment figures will come out at 10 a.m. ET.

 

Today’s indications:

  • The iShares Nasdaq Biotechnology (IBB) is NOT indicating in Friday’s pre-market;
  • The SPDR S&P Biotech ETF (XBI) is NOT indicating in Friday’s pre-market;
  • The Health Care Select Sector SPDR ETF (XLV) is indicating a POSITIVE +0.02% upside in Friday’s pre-open;
  • The iShares Russell 2000 (IWM) is indicating a NEGATIVE -0.19% downside in Friday’s pre-open

 

Henry’omics:

Today’s moves:  A bit hesitant with my prognostic “eyes”, after a big jump in the A/DL (advance/decline line), low volume, weakened technicals, dramatic upside volatility, questionable relative strength – have I listed enough – I’d skim and take some profit from many of the upsides.

 

From Thursday’s night’s newsletter: “…a rally finish and a sigh of relief … Next issue – which pricing is sustainable? One issue – low volume with good moves as volatility could be suspect; second issue – few if any headline; third issue – risk is hyped as many upsides could be “harvested.”

 

Review the 5 sessions of 40 covered companies:

  • Thursday closed POSITIVE with 18 decliners, 21 advancers and 1 flat;
  • Wednesday closed NEGATIVE with 22 decliners, 15 advancers and 3 flats;
  • Tuesday closed NEGATIVE with 25 decliners, 9 advancers and 6 flats;
  • Monday closed NEGATIVE with 28 decliners, 7 advancers and 5 flat;
  • Last Friday closed NEGATIVE with 22 decliners, 12 advancers and 6 flat;

 

A re-cap:

  • There have been 19 sessions in April,  there have been eleven (11) negative closes,  seven (7) positive closes and one (1) neutral close (of 40 covered companies);
  • In the last six (6) sessions, the iShares NASDAQ Biotechnology (IBB) was down in five (5) and up in one (1) session for an aggregate of positive +1.85% after Thursday’s +1. 98%, Wednesday’s -0.01%, Tuesday’s -1.445%, Monday (-0.16%), Friday (-0.88%) and last Thursday (-1.36);
  • Thursday’s gainers ranged from +0.30% <BCLI +$0.01> to +9.41% <VTGN +$0.08 > in 21 equities;
  • Thursday’s decliners ranged from -0.75% <CAPR -$0.01> to -6.07% <SGMO -$1.05 > in 18 equities;

 

My daily evaluation:  As I had stated in the title, “There will be a tug-of-war to retain the pricing.”

 

Company in my headlights:

MiMedx Group (MDXG) closed down -$0.32 to $7.92 with 2.9 M shares traded<3 month average = 3.57 M>.  +$0.81 to $8.24 (+10.90% increase) with 4.73 M shares traded. Q1/18 earnings were approximated to be good and the shares were down as I am remembering 1/29/18’s pricing $17.96 – Maintaining BUY:

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.